"AstraZeneca’s Farxiga (dapagliflozin) has been approved in the US to reduce the risk of cardiovascular (CV) death and hospitalisation for heart failure in adults with heart failure (NYHA class II-IV) with reduced ejection fraction (HFrEF) with and without type-2 diabetes (T2D)." ( bolding added)
Is ABL just as effective in patients without type-2 diabetes as it is with, as found in the BOM trial?
Koo